Antonio Colecchia

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6407755/publications.pdf

Version: 2024-02-01

53794 64796 7,072 161 45 79 citations h-index g-index papers 165 165 165 8884 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Size and location of spontaneous portosystemic shunts predict the risk of decompensation in cirrhotic patients. Digestive and Liver Disease, 2022, 54, 103-110.	0.9	22
2	Validation of a standardized CT protocol for the evaluation of varices and porto-systemic shunts in cirrhotic patients. European Journal of Radiology, 2022, 147, 110010.	2.6	13
3	Segmental Distribution of Hepatocellular Carcinoma in Cirrhotic Livers. Diagnostics, 2022, 12, 834.	2.6	6
4	Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia. Cancer Medicine, 2022, 11, 618-629.	2.8	3
5	Sarcopenia Predicts Major Complications after Resection for Primary Hepatocellular Carcinoma in Compensated Cirrhosis. Cancers, 2022, 14, 1935.	3.7	14
6	Distinguishing features between patients with acute diverticulitis and diverticular bleeding: Results from the REMAD registry. Digestive and Liver Disease, 2021, 53, 202-209.	0.9	5
7	Gut microbiota signatures and clinical manifestations in celiac disease children at onset: a pilot study. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 446-454.	2.8	37
8	Clinical impact of sarcopenia assessment in patients with liver cirrhosis. Expert Review of Gastroenterology and Hepatology, 2021, 15, 377-388.	3.0	15
9	Imaging Software-Based Sarcopenia Assessment in Gastroenterology: Evolution and Clinical Meaning. Canadian Journal of Gastroenterology and Hepatology, 2021, 2021, 1-7.	1.9	8
10	Liver and Spleen Stiffness in Vascular Liver Disease. , 2021, , 235-255.		0
11	A Nomogram-Based Prognostic Model for Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib: A Multicenter Study. Cancers, 2021, 13, 2677.	3.7	6
12	Prognostic Value of the Albumin-Bilirubin Grade for the Prediction of Post-Hepatectomy Liver Failure: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2021, 10, 2011.	2.4	16
13	The role of liver and spleen elastography in advanced chronic liver disease. Minerva Gastroenterology, 2021, 67, 151-163.	0.5	4
14	Elastography: where are we now?. Minerva Gastroenterology, 2021, 67, .	0.5	4
15	Risk of hepatocellular carcinoma after HCV eradication: Determining the role of portal hypertension by measuring spleen stiffness. JHEP Reports, 2021, 3, 100289.	4.9	12
16	Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study Digestive and Liver Disease, 2021, 53, 1011-1019.	0.9	7
17	Antibiotic prophylaxis in patients with cirrhosis: Current evidence for clinical practice. World Journal of Hepatology, 2021, 13, 840-852.	2.0	1
18	Clinical Presentation of Celiac Disease and Diagnosis Accuracy in a Single-Center European Pediatric Cohort over 10 Years. Nutrients, 2021, 13, 4131.	4.1	0

#	Article	IF	CITATIONS
19	A novel spleenâ€dedicated stiffness measurement by FibroScan® improves the screening of highâ€risk oesophageal varices. Liver International, 2020, 40, 175-185.	3.9	60
20	Liver fibrosis by FibroScan ^{$\hat{A}^@$} independently of established cardiovascular risk parameters associates with macrovascular and microvascular complications in patients with type 2 diabetes. Liver International, 2020, 40, 347-354.	3.9	59
21	Screening for non-alcoholic fatty liver disease using liver stiffness measurement and its association with chronic kidney disease and cardiovascular complications in patients with type 2 diabetes. Diabetes and Metabolism, 2020, 46, 296-303.	2.9	47
22	NAFLD fibrosis score (NFS) can be used in outpatient services to identify chronic vascular complications besides advanced liver fibrosis in type 2 diabetes. Journal of Diabetes and Its Complications, 2020, 34, 107684.	2.3	11
23	Spleen Stiffness Measurements Predict the Risk of Hepatic Decompensation After Direct-Acting Antivirals in HCV Cirrhotic Patients. Ultraschall in Der Medizin, 2020, , .	1.5	15
24	Clinical impact of sarcopenia assessment in patients with hepatocellular carcinoma undergoing treatments. Journal of Gastroenterology, 2020, 55, 927-943.	5.1	70
25	Is Ultrasound Elastography Useful in Predicting Clinically Relevant Pancreatic Fistula After Pancreatic Resection?. Pancreas, 2020, 49, 1342-1347.	1.1	4
26	Probiotics, Prebiotics and Other Dietary Supplements for Gut Microbiota Modulation in Celiac Disease Patients. Nutrients, 2020, 12, 2674.	4.1	47
27	Clinical outcomes after treatment with direct-acting antivirals: not all concern hepatocellular carcinoma risk. Hepatobiliary Surgery and Nutrition, 2020, 9, 505-507.	1.5	3
28	Spleen stiffness measurement for assessing the response to \hat{l}^2 -blockers therapy for high-risk esophageal varices patients. Hepatology International, 2020, 14, 850-857.	4.2	41
29	<i>PNPLA3</i> I148M gene variant and chronic kidney disease in type 2 diabetic patients with NAFLD: Clinical and experimental findings. Liver International, 2020, 40, 1130-1141.	3.9	33
30	Imaging in Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome. Biology of Blood and Marrow Transplantation, 2020, 26, 1770-1779.	2.0	26
31	Diagnosis and Treatment of VOD/SOS After Allogeneic Hematopoietic Stem Cell Transplantation. Frontiers in Immunology, 2020, 11, 489.	4.8	90
32	Pancreatic ultrasound elastography is not useful to predict the risk of pancreatic fistulas after pancreatic resection. Updates in Surgery, 2020, 72, 1081-1087.	2.0	4
33	The Onset of de novo Hepatocellular Carcinoma after Liver Transplantation can be both of Donor and Recipient origin. A Case Report. Journal of Gastrointestinal and Liver Diseases, 2020, 24, 387-389.	0.9	7
34	Adverse Food Reaction and Functional Gastrointestinal Disorders: Role of the Dietetic Approach. Journal of Gastrointestinal and Liver Diseases, 2020, 24, 319-327.	0.9	11
35	Non-invasive tests for the prediction of primary hepatocellular carcinoma. World Journal of Gastroenterology, 2020, 26, 3326-3343.	3.3	28
36	Sound Conclusions: How Splenic Elastography May Decrease the Need for Endoscopic Variceal Surveillance. Digestive Diseases and Sciences, 2019, 64, 2381-2383.	2.3	0

#	Article	IF	CITATIONS
37	Liver Stiffness Measurement Allows Early Diagnosis of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome in Adult Patients Who Undergo Hematopoietic Stem Cell Transplantation: Results from a Monocentric Prospective Study. Biology of Blood and Marrow Transplantation, 2019, 25, 995-1003.	2.0	56
38	Reply to correspondence concerning: "Role of liver and spleen stiffness in predicting the recurrence of hepatocellular carcinoma after resection― Journal of Hepatology, 2019, 70, 809-810.	3.7	2
39	The concept of therapeutic hierarchy for patients with hepatocellular carcinoma: A multicenter cohort study. Liver International, 2019, 39, 1478-1489.	3.9	41
40	Indocyanine green retention test predict the risk of portal hypertension-related events after direct-acting antiviral therapy in compensated advanced chronic liver disease patients. Digestive and Liver Disease, 2019, 51, e55.	0.9	0
41	The risk of hepatic decompensation is reduced, but not abolished after direct-acting antivirals: the role of spleen stiffness measurement. Digestive and Liver Disease, 2019, 51, e64.	0.9	0
42	Role of imaging techniques in liver veno-occlusive disease diagnosis: recent advances and literature review. Expert Review of Gastroenterology and Hepatology, 2019, 13, 463-484.	3.0	34
43	Liver and Spleen Stiffness Measurements for Assessment of Portal Hypertension Severity in Patients with Budd Chiari Syndrome. Canadian Journal of Gastroenterology and Hepatology, 2019, 2019, 1-6.	1.9	22
44	Association between PNPLA3rs738409 polymorphism decreased kidney function in postmenopausal type 2 diabetic women with or without non-alcoholic fatty liver disease. Diabetes and Metabolism, 2019, 45, 480-487.	2.9	36
45	Prediction of posthepatectomy liver failure: Role of SSM and LSPS. Journal of Surgical Oncology, 2019, 119, 400-401.	1.7	10
46	"Are the Expanded Baveno VI Criteria really safe to screen compensated cirrhotic patients for high-risk varices?― Digestive and Liver Disease, 2019, 51, 456-457.	0.9	12
47	Association between non-alcoholic fatty liver disease and bone turnover biomarkers in post-menopausal women with type 2 diabetes. Diabetes and Metabolism, 2019, 45, 347-355.	2.9	47
48	Role of liver and spleen stiffness in predicting the recurrence of hepatocellular carcinoma after resection. Journal of Hepatology, 2019, 70, 440-448.	3.7	126
49	Vascular and Parenchymal Alterations of the Liver and Liver Surveillance in Patients Who Received Inotuzumab Ozogamicin As the Standard of Care for Relapse/Refractory Acute Lymphoblastic Leukemia. Blood, 2019, 134, 1343-1343.	1.4	1
50	Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals. Digestive and Liver Disease, 2018, 50, 573-579.	0.9	56
51	Persistent Fever and Abdominal Pain in a Young Woman With Budd-Chiari Syndrome. Gastroenterology, 2018, 154, 495-497.	1.3	5
52	Utility of Tumor Burden Score to Stratify Prognosis of Patients with Hepatocellular Cancer: Results of 4759 Cases from ITA.LI.CA Study Group. Journal of Gastrointestinal Surgery, 2018, 22, 859-871.	1.7	38
53	A combined model based on spleen stiffness measurement and Baveno VI criteria to rule out high-risk varices in advanced chronic liver disease. Journal of Hepatology, 2018, 69, 308-317.	3.7	142
54	Spleen Stiffness by Ultrasound Elastography. , 2018, , 113-137.		7

#	Article	IF	CITATIONS
55	Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice. Hepatology, 2018, 67, 1784-1796.	7.3	93
56	Restaging Patients With Hepatocellular Carcinoma Before Additional Treatment Decisions: A Multicenter Cohort Study. Hepatology, 2018, 68, 1232-1244.	7.3	26
57	Spleen stiffness mirrors changes in portal hypertension after successful interferon-free therapy in chronic-hepatitis C virus patients. World Journal of Hepatology, 2018, 10, 731-742.	2.0	24
58	Transient Elastography Anticipates the Diagnosis of VOD/SOS after Adult Allogeneic Stem Cell Transplant: Results from a Prospective Study. Blood, 2018, 132, 2098-2098.	1.4	0
59	Adding Liver Stiffness Measurement to the Routine Evaluation of Hepatocellular Carcinoma Resectability CanÂOptimize Clinical Outcome. Ultraschall in Der Medizin, 2017, 38, 515-522.	1.5	3
60	A metaâ€analysis of single <scp>HCV</scp> â€untreated arm of studies evaluating outcomes after curative treatments of <scp>HCV</scp> â€related hepatocellular carcinoma. Liver International, 2017, 37, 1157-1166.	3.9	70
61	Primary biliary cholangitis–primary sclerosing cholangitis in an evolving overlap syndrome: A case report. GastroenterologÃa Y HepatologÃa, 2017, 40, 669-671.	0.5	8
62	Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma. Journal of Hepatology, 2017, 67, 65-71.	3.7	83
63	Gut microbiota, metabolome and immune signatures in patients with uncomplicated diverticular disease. Gut, 2017, 66, 1252-1261.	12.1	138
64	Ductal stones recurrence after extracorporeal shock wave lithotripsy for difficult common bile duct stones: Predictive factors. Digestive and Liver Disease, 2017, 49, 1128-1132.	0.9	2
65	Liver stiffness and serum fibrosis biomarker variations after DAAs treatment: Predictive role in HCC development in cirrhotic patients. Digestive and Liver Disease, 2017, 49, e39.	0.9	0
66	Spleen stiffness measurement: A useful prognostic tool in HCV patients treated with DAAs regimens. Digestive and Liver Disease, 2017, 49, e40-e41.	0.9	0
67	Differences in liver stiffness values obtained with new ultrasound elastography machines and Fibroscan: A comparative study. Digestive and Liver Disease, 2017, 49, 802-808.	0.9	51
68	Usefulness of liver stiffness measurement in predicting hepatic veno-occlusive disease development in patients who undergo HSCT. Bone Marrow Transplantation, 2017, 52, 494-497.	2.4	34
69	Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of <scp>HCV</scp> eradication does not depend on the use of interferon. Alimentary Pharmacology and Therapeutics, 2017, 45, 160-168.	3.7	70
70	The evolutionary scenario of hepatocellular carcinoma in Italy: an update. Liver International, 2017, 37, 259-270.	3.9	67
71	Relationship between indocyanine green retention test, decompensation and survival in patients with Childâ€Pugh A cirrhosis and portal hypertension. Liver International, 2016, 36, 1313-1321.	3.9	29
72	Su1942 Mucosal Immune System and Its Interaction With Microbiota in Patients With Diverticular Disease. Gastroenterology, 2016, 150, S595.	1.3	0

#	Article	IF	Citations
73	MRI Patterns in a Case of 6-Thioguanine-Related Hepatic Sinusoidal Obstruction Syndrome. American Journal of Gastroenterology, 2016, 111, 767.	0.4	7
74	Are Noninvasive Methods Clinically Useful in Advanced, Decompensated Liver Cirrhosis When "Les Jeux Sont Faits�. Radiology, 2016, 278, 304-306.	7.3	2
75	Gut Microbiota and Celiac Disease. Digestive Diseases and Sciences, 2016, 61, 1461-1472.	2.3	115
76	Hepatic venous pressure gradient in the preoperative assessment of patients with resectable hepatocellular carcinoma. Journal of Hepatology, 2016, 64, 79-86.	3.7	83
77	Pathophysiology and Therapeutic Strategies for Symptomatic Uncomplicated Diverticular Disease of the Colon. Digestive Diseases and Sciences, 2016, 61, 673-683.	2.3	25
78	Liver and spleen stiffness and other noninvasive methods to assess portal hypertension in cirrhotic patients. European Journal of Gastroenterology and Hepatology, 2015, 27, 992-1001.	1.6	51
79	Ischaemiaâ€modified albumin: a marker of bacterial infection in hospitalized patients with cirrhosis. Liver International, 2015, 35, 2425-2432.	3.9	20
80	Reply to Letter. Annals of Surgery, 2015, 261, e105-e106.	4.2	1
81	Non-invasive diagnostic approach to non-alcoholic fatty liver disease: current evidence and future perspectives. Expert Review of Gastroenterology and Hepatology, 2015, 9, 1039-1053.	3.0	13
82	Transient Elastography (FibroScan) Is Not Correlated With Liver Fibrosis but With Cholestasis in Patients With Longâ€Term Home Parenteral Nutrition. Journal of Parenteral and Enteral Nutrition, 2015, 39, 719-724.	2.6	51
83	Risk Factors for Gallstone Formation During Weight Loss. Clinical Gastroenterology and Hepatology, 2015, 13, 613.	4.4	8
84	Dysbiosis in Celiac Disease Patients With Persistent Symptoms on Gluten-Free Diet: A Condition Similar to that Present in Irritable Bowel Syndrome Patients?. American Journal of Gastroenterology, 2015, 110, 598.	0.4	11
85	Gut microbiota and metabolic syndrome. World Journal of Gastroenterology, 2014, 20, 16079.	3.3	405
86	Prognostic factors for hepatocellular carcinoma recurrence. World Journal of Gastroenterology, 2014, 20, 5935.	3.3	143
87	Indocyanine green retention test as a noninvasive marker of portal hypertension and esophageal varices in compensated liver cirrhosis. Hepatology, 2014, 59, 643-650.	7.3	91
88	An explorative data-analysis to support the choice between hepatic resection and radiofrequency ablation in the treatment of hepatocellular carcinoma. Digestive and Liver Disease, 2014, 46, 257-263.	0.9	43
89	Spleen stiffness measurement can predict clinical complications in compensated HCV-related cirrhosis: A prospective study. Journal of Hepatology, 2014, 60, 1158-1164.	3.7	123
90	Italian consensus conference for colonic diverticulosis and diverticular disease. United European Gastroenterology Journal, 2014, 2, 413-442.	3.8	141

#	Article	IF	Citations
91	Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma. Journal of Hepatology, 2013, 59, 300-307.	3.7	323
92	A new point-of-care portable immunosensor for non-invasive assessment of oro-ileal transit time by oral fluid tauroursodeoxycholate measurement after its oral load. Journal of Pharmaceutical and Biomedical Analysis, 2013, 81-82, 1-7.	2.8	1
93	Review article: the diagnosis of nonâ€alcoholic fatty liver disease – availability and accuracy of nonâ€invasive methods. Alimentary Pharmacology and Therapeutics, 2013, 37, 392-400.	3.7	156
94	Letter: FibroTest for staging fibrosis in nonâ€alcoholic fatty liver disease – authors' reply. Alimentary Pharmacology and Therapeutics, 2013, 37, 656-657.	3.7	6
95	Focal nodular hyperplasia of the liver in children after hematopoietic stem cell transplantation. Pediatric Transplantation, 2013, 17, 479-486.	1.0	16
96	Benign Hepatic Nodular Lesions After Treatment for Childhood Cancer. Journal of Pediatric Gastroenterology and Nutrition, 2013, 56, 151-155.	1.8	16
97	Long-term leukocyte natural \hat{l}_{\pm} -interferon and ribavirin treatment in hepatitis C virus recurrence after liver transplantation. World Journal of Gastroenterology, 2013, 19, 5278.	3.3	3
98	Value of Transient Elastography Measured With Fibroscan in Predicting the Outcome of Hepatic Resection for Hepatocellular Carcinoma. Annals of Surgery, 2012, 256, 706-713.	4.2	142
99	Noninvasive Parameters for Predicting Esophageal Varices in Children: Their Sequential Use Provides the Best Accuracy. Gastroenterology, 2012, 142, e32.	1.3	3
100	Measurement of Spleen Stiffness to Evaluate Portal Hypertension and the Presence of Esophageal Varices in Patients With HCV-Related Cirrhosis. Gastroenterology, 2012, 143, 646-654.	1.3	440
101	Relationship between hepatic haemodynamics assessed by Doppler ultrasound and liver stiffness. Digestive and Liver Disease, 2012, 44, 154-159.	0.9	18
102	Long-Term Treatment With Natural Alpha-IFN in Hepatitis C Recurrence After OLT. Gastroenterology, 2011, 140, S-901.	1.3	0
103	Coeliac disease and autoimmune hepatitis: Gluten-free diet can influence liver disease outcome. Digestive and Liver Disease, 2011, 43, 247.	0.9	7
104	Non-invasive methods can predict oesophageal varices in patients with biliary atresia after a Kasai procedure. Digestive and Liver Disease, 2011, 43, 659-663.	0.9	41
105	Indocyanine Green Clearance as a Marker of Decompensation and Clinically Significant Portal Hypertension in Patients With Liver Cirrhosis. Gastroenterology, 2011, 140, S-958.	1.3	1
106	Pre-operative liver biopsy in cirrhotic patients with early hepatocellular carcinoma represents a safe and accurate diagnostic tool for tumour grading assessment. Journal of Hepatology, 2011, 54, 300-305.	3.7	58
107	Plasma antioxidant enzymes and clastogenic factors as possible biomarkers of colorectal cancer risk. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2011, 714, 88-92.	1.0	23
108	Gut Microbiota and Its Pathophysiology in Disease Paradigms. Digestive Diseases, 2011, 29, 518-524.	1.9	50

#	Article	IF	CITATIONS
109	Focal nodular hyperplasia of the liver after intensive treatment for pediatric cancer: is hematopoietic stem cell transplantation a risk factor?. European Journal of Pediatrics, 2011, 170, 807-812.	2.7	20
110	Percutaneous liver biopsy in the clinical management of hepatocellular carcinoma: Back to the future. Hepatology, 2011, 53, 2147-2147.	7.3	O
111	Autoimmune liver diseases in a paediatric population with coeliac disease – a 10â€year singleâ€centre experience. Alimentary Pharmacology and Therapeutics, 2010, 31, 253-260.	3.7	42
112	Natural history of gallstone disease: Expectant management or active treatment? Results from a populationâ€based cohort study. Journal of Gastroenterology and Hepatology (Australia), 2010, 25, 719-724.	2.8	130
113	Development and application of a simple and powerful tool for nutrition and lifestyle education for the Italian general population by general practitioners and family paediatricians. Mediterranean Journal of Nutrition and Metabolism, 2009, 2, 139-144.	0.5	2
114	Body weight, lifestyle, dietary habits and gastroesophageal reflux disease. World Journal of Gastroenterology, 2009, 15, 1690.	3.3	138
115	Mesalazine and Rifaximin in Symptomatic Uncomplicated Diverticular Disease. American Journal of Gastroenterology, 2009, 104, 532-532.	0.4	3
116	Development and application of a simple and powerful tool for nutrition and lifestyle education for the Italian general population by general practitioners and family paediatricians. Mediterranean Journal of Nutrition and Metabolism, 2009, 2, 139-144.	0.5	6
117	Methodology and Indications of H ₂ â€Breath Testing in Gastrointestinal Diseases: the Rome Consensus Conference. Alimentary Pharmacology and Therapeutics, 2009, 29, 1-49.	3.7	320
118	Natural History of Small Gallbladder Polyps Is Benign: Evidence From a Clinical and Pathogenetic Study. American Journal of Gastroenterology, 2009, 104, 624-629.	0.4	32
119	Bacterial flora, gas and antibiotics. Digestive and Liver Disease Supplements, 2009, 3, 54-57.	0.2	1
120	C-11 Acetate Does Not Enhance Usefulness of F-18 FDG PET/CT in Differentiating Between Focal Nodular Hyperplasia and Hepatic Adenoma. Clinical Nuclear Medicine, 2009, 34, 659-665.	1.3	21
121	Natural History of Small Gallbladder Polyps Is Benign. American Journal of Gastroenterology, 2009, 104, 624-629.	0.4	7
122	Clinical trial: pegâ€interferon alfaâ€2b and ribavirin for the treatment of genotypeâ€1 hepatitis C recurrence after liver transplantation. Alimentary Pharmacology and Therapeutics, 2008, 28, 450-457.	3.7	39
123	Transjugular intrahepatic portosystemic shunt: A case report of rescue management of unrestrainable variceal bleeding in a pregnant woman. Digestive and Liver Disease, 2008, 40, 387-390.	0.9	29
124	Incidence of gallstone disease in Italy: Results from a multicenter, population-based Italian study (the) Tj ETQq0	0 0 ₃ rgBT /	Overlock 10 T
125	Clinical Efficacy and Effectiveness of Ursodeoxycholic Acid in Cholestatic Liver Diseases. Current Clinical Pharmacology, 2007, 2, 155-177.	0.6	49
126	Biliary symptoms, gallbladder motility, and cholecystectomy. Hepatology, 2007, 45, 259-260.	7.3	0

#	Article	IF	Citations
127	Clinical trial: modulation of human placental multidrug resistance proteins in cholestasis of pregnancy by ursodeoxycholic acid. Alimentary Pharmacology and Therapeutics, 2007, 26, 1139-1146.	3.7	41
128	Efficacy of long term cyclic administration of the poorly absorbed antibiotic Rifaximin in symptomatic, uncomplicated colonic diverticular disease. World Journal of Gastroenterology, 2007, 13, 264.	3.3	91
129	Management of Hepatic Encephalopathy: Focus on Antibiotic Therapy. Digestion, 2006, 73, 94-101.	2.3	45
130	Systemic lupus erythematosus following virological response to peginterferon alfa-2b in a transplanted patient with chronic hepatitis C recurrence. World Journal of Gastroenterology, 2006, 12, 4253.	3.3	15
131	Is It Possible to Predict the Clinical Course of Gallstone Disease? Usefulness of Gallbladder Motility Evaluation in a Clinical Setting. American Journal of Gastroenterology, 2006, 101, 2576-2581.	0.4	25
132	Ursodeoxycholic acid improves gastrointestinal motility defects in gallstone patients. World Journal of Gastroenterology, 2006, 12, 5336.	3.3	17
133	Hepatocellular carcinoma prevention: A worldwide emergence between the opulence of developed countries and the economic constraints of developing nations. World Journal of Gastroenterology, 2006, 12, 7239.	3.3	74
134	Higher doses of peginterferon alpha-2b administered twice weekly improve sustained virological response in difficult-to-treat patients with chronic hepatitis C: results of a pilot randomized study. Journal of Viral Hepatitis, 2005, 12, 536-542.	2.0	13
135	Measurement of hepatic functional mass by means of 13C-methacetin and 13C-phenylalanine breath tests in chronic liver disease: Comparison with Child-Pugh score and serum bile acid levels. World Journal of Gastroenterology, 2005, 11, 142.	3.3	51
136	Interferon plus ribavirin and interferon alone in preventing hepatocellular carcinoma: A prospective study on patients with HCV related cirrhosis. World Journal of Gastroenterology, 2004, 10, 3099.	3.3	38
137	Hepatic steatosis in obese patients: clinical aspects and prognostic significance. Obesity Reviews, 2004, 5, 27-42.	6.5	263
138	Safety of interferon \hat{l}^2 treatment for chronic HCV hepatitis. World Journal of Gastroenterology, 2004, 10, 12.	3.3	48
139	Six years follow-up in primary biliary cirrhosis patients: Evaluation of standard vs high UDCA dose on liver biochemistry, Mayo score and liver histology. Gastroenterology, 2003, 124, A712.	1.3	0
140	Interferon and interferon plus ribavirine in hepatocellular carcinoma prevention: A prospective study on patients with HCV related cirrhosis. Gastroenterology, 2003, 124, A703.	1.3	0
141	Measurements of gallbladder motor function by ultrasonography: towards standardization. Digestive and Liver Disease, 2003, 35, 56-61.	0.9	29
142	Ten year incidence of HCV infection in northern Italy and frequency of spontaneous viral clearance. Gut, 2003, 52, 1030-1034.	12.1	59
143	Diverticular disease of the colon: New perspectives in symptom development and treatment. World Journal of Gastroenterology, 2003, 9, 1385.	3.3	51
144	Gastric autoimmune disorders in patients with chronic hepatitis C before, during and after interferon-alpha therapy. World Journal of Gastroenterology, 2003, 9, 1487.	3.3	29

#	Article	IF	Citations
145	Long-term alpha interferon and lamivudine combination therapy in non-responder patients with anti-HBe-positive chronic hepatitis B: Results of an open, controlled trial. World Journal of Gastroenterology, 2003, 9, 1491.	3.3	21
146	Improved liver tests and greater biliary enrichment with high dose ursodeoxycholic acid in early stage primary biliary cirrhosis. Digestive and Liver Disease, 2002, 34, 523-527.	0.9	17
147	Ten-year incidence of HCV infection in northern Italy and frequency of spontaneous viral clearance. Journal of Hepatology, 2002, 36, 119.	3.7	1
148	Incidence and natural history of HCV infection in Northern Italy: Results of an epidemiological study. Gastroenterology, 2001, 120, A366.	1.3	0
149	Review: low caloric intake and gall-bladder motor function. Alimentary Pharmacology and Therapeutics, 2000, 14, 51-53.	3.7	37
150	Incidence and natural history of HCV infection: Results of an epidemiological study. Gastroenterology, 2000, 118, A952-A953.	1.3	0
151	Orocecal transit time in gallstone patients and in obese patients before and after very low calorie diet. Gastroenterology, 2000, 118, A1497.	1.3	0
152	Does gallbladder motility relate to biliary symptom frequency in cholesterol gallstone patients?. Gastroenterology, 2000, 118, A1002.	1.3	0
153	Efficacy and safety of long term treatment of chronic hepatitis B with IFNA plus lamivudine versus IFNA alone. Gastroenterology, 2000, 118, A937.	1.3	1
154	Changes in biliary lipid secretion and cholic acid kinetics induced by diet and diet + simvastatin in obese subjects. Gastroenterology, 2000, 118, A927.	1.3	0
155	Standards for diagnosis gastrointestinal motility disorders. Section: ultrasonography position statement from the Gruppo Italiano di Studio MotilitA Apparato Digerente (GISMAD). Digestive and Liver Disease, 2000, 32, 160-172.	0.9	29
156	Sluggish Small Bowel Motility Is Involved in Determining Increased Biliary Deoxycholic Acid in Cholesterol Gallstone Patients. American Journal of Gastroenterology, 1999, 94, 2453-2459.	0.4	25
157	Clinical manifestations of gallstone disease: Evidence from the multicenter Italian study on cholelithiasis (MICOL). Hepatology, 1999, 30, 839-846.	7. 3	84
158	Gallbladder motility and gallstone formation in obese patients following very low calorie diets. Use it (fat) to lose it (well). International Journal of Obesity, 1998, 22, 592-600.	3.4	71
159	Endoscopic Ultrasonography in the Diagnosis of Gastrointestinal Amyloid Deposits: Clinical Case Report. Endoscopy, 1995, 27, 132-134.	1.8	13
160	Natural history of hepatic haemangiomas: clinical and ultrasound study Gut, 1991, 32, 677-680.	12.1	190
161	Non-invasive tests for the prediction of post-hepatectomy liver failure in the elderly. Hepatoma Research, 0, 2020, .	1.5	3